In this Issue
Volume 2 Issue 9
Feature and Monograph:
Trilostane Gourmeds™
News and Notes:
Pimobendan is FDA Approved; WW Won't Compound Routinely
New Pharmacy Technician Program Approved
Profit
by This:
New
Profit Solver Software Boosts Revenue
Sound
off and profit, too: The VetZone
In
the News:
FDA
Credits Compounders' Efforts to Stifle New Regulation
Upcoming Events:
CVC Central and West
Dr.
Dean Richardson at AAEP
Another Opinion:
"The
Assault Must Be Rejected"
| Special Pricing: | ||||||
|
Trilostane Gourmeds™ |
||||||
|
|
||||||
|
Featured Monograph: Trilostane for veterinary use is a competitive inhibitor of the enzyme 3-beta hydroxysteroid dehydrogenase. It works at the level of the adrenal gland to block the normal steroidogenisis pathway of pregnenolone to progesterone to cortisol, aldosterone, and androstenedione. Pituitary dependant hyperadrenocorticism (PDH) is the most common cause of Cushing's disease seen in dogs. More >> | |||||
|
|
||||||
| Pimobendan (Vetmedin) is FDA Approved | ||||||
| This
medication is now FDA approved and available through normal veterinary
distribution channels. Wedgewood Pharmacy will no longer routinely
compound this drug after September 6, 2007. The FDA-approved
product is available in flavored, chewable tablets in the most common
strengths, 1.25 mg. and 5 mg. Wedgewood will compound Pimobendan
when a veterinarian prescribes a custom strength or dosage form or
if a patient is sensitive or allergic to a non-active component in
the manufactured product. For further information: 1-888-678-1967 |
||||||
|
|
||||||
| Wedgewood's
New Technician Training Program |
 |
|||||
| A new, 14-module regulatory and technical program, designed by Eden M. Venti, Wedgewood's head of Quality Assurance and Regulatory Affairs, was approved by the board of the New Jersey State Board of Pharmacy and began in mid-August. The program is one of many quality and safety initiatives that are part of Wedgewood's commitment to high product and ethical standards. Each year, the company provides a total of more than 800 hours — more than 100 business days — of initial and continuing education to its cadre of technicians. | ||||||
|
|
||||||
| Profit By This: | |
| New Software | The VetZone |
 |
 |
|
This
new
software optimizes fee structures and provide the exact profit in
each minute charged by billable staff. Helps set fees
to achieve predetermined profit goal. One vet says it boosted
his three-vet practice's revenue by $200K. |
Earn
cash and let your voice be heard. Register with this panel of nearly
4,000 vets and earn honoraria for taking online surveys. |
|
|
|
|
|
|
|
Did You Know? Every prescription from Wedgewood is checked and signed by at least five registered pharmacists. |
|
|
| Upcoming Events: | |
|
|
|
  |
|
|
|
|
|
AAEP 53rd Annual Convention, Orlando,
December 1 - 5, with Dr. Dean Richardson as keynote
speaker giving the Lessons Learned From the Barbaro Experience
presentation that drew a standing-room-only crowd at the recent
Hambletonian Seminar.
Information >> |
|
 |
|
|
|
|
| Another Opinion: | |
 |
|
|
|
|
| In the News: | |
| FDA Credits Compounders with Legislative Win: | |
 |
|
|
Reporting on draft legislation by Sens. Kennedy, Burr and Roberts
that would "clarify" the FDA's role in regulating
compounding, The FDA Drug Daily Bulletin noted that
"organizations representing more than 60,000 pharmacists ...
sent a letter to the bill's authors, discouraging them from
introducing it." The bill has never been introduced.
The proposal, which would have made it virtually impossible to obtain
compounded medica-tions, was opposed by "pharm-acists, the
autism community, women's health advocates and tens of thousands
of patients and prescribers."
Add your letter to the tens of thousands opposing this still-pending legislation. |
|
|
|
|
This
newsletter is published every month by Wedgewood Pharmacy,
one of the nation's largest veterinary compounding pharmacies.
405 Heron Drive STE 200 • Swedesboro NJ 08085-1749 • 1.800.331.8272
Copyright
© 2007 Wedgewood Village Pharmacy, Inc. All rights reserved.
